PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
30 sept. 2015 09h30 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - September 30, 2015) - Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
18 mars 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
14 oct. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
07 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA...
Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist
05 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 5, 2014) - Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer...
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
19 févr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer
11 sept. 2013 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 11, 2013) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration's...
FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
09 sept. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...